Literature DB >> 8592665

The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats.

M Vakily1, B Corrigan, F Jamali.   

Abstract

PURPOSE: A comparison of a previously reported indirect (precolumn derivatization) assay for ketorolac (KT) and a new direct method described here was made to establish the conditions under which KT may undergo racemization and to explain the observed discrepancies in the pharmacokinetics of KT reported in the literature.
METHODS: A previously reported pre-column derivatization method and a new direct method were employed to determine the effect of pH and ionic strength on racemization. Using the conditions where no racemization occurred, the pharmacokinetics in humans and rats, and protein binding of KT enantiomers were determined.
RESULTS: Under the chromatographic conditions employed for the direct assay, no racemization was observed. Under high pH and ionic strength, however, both methods resulted in KT racemization. The indirect method resulted in rapid and complete racemization due to the strong basic conditions required for derivatization. In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45). This is likely due to more extensive plasma protein binding of S than its antipode (unbound S/R: 1.35).
CONCLUSIONS: The discrepancies in the literature may be explained by rapid racemization of KT that occurs during sample preparation for the pre-column derivatization method. Considerations should be given to the possibility of racemization during the assay development and validation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592665     DOI: 10.1023/a:1016245101389

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

Review 1.  Enantioselective aspects of drug action and disposition: therapeutic pitfalls.

Authors:  F Jamali; R Mehvar; F M Pasutto
Journal:  J Pharm Sci       Date:  1989-09       Impact factor: 3.534

2.  Limited extent of stereochemical conversion of chiral non-steroidal anti-inflammatory drugs induced by derivatization methods employing ethyl chloroformate.

Authors:  M R Wright; F Jamali
Journal:  J Chromatogr       Date:  1993-06-23

Review 3.  The so-called "interconversion" of stereoisomeric drugs: an attempt at clarification.

Authors:  B Testa; P A Carrupt; J Gal
Journal:  Chirality       Date:  1993       Impact factor: 2.437

Review 4.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

5.  Marked enantioselective protein binding in humans of ketorolac in vitro: elucidation of enantiomer unbound fractions following facile synthesis and direct chiral HPLC resolution of tritium-labelled ketorolac.

Authors:  P J Hayball; J W Holman; R L Nation; R A Massy-Westropp; D P Hamon
Journal:  Chirality       Date:  1994       Impact factor: 2.437

6.  Stereoselective analysis of ketorolac in human plasma by high-performance liquid chromatography.

Authors:  P J Hayball; J G Tamblyn; Y Holden; J Wrobel
Journal:  Chirality       Date:  1993       Impact factor: 2.437

7.  The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.

Authors:  P J Hayball; J Wrobel; J G Tamblyn; R L Nation
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

8.  Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans.

Authors:  F Jamali; R Mehvar; C Lemko; O Eradiri
Journal:  J Pharm Sci       Date:  1988-11       Impact factor: 3.534

  8 in total
  4 in total

Review 1.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.

Authors:  Yuna Guo; S Ray Kenney; Linda Cook; Sarah F Adams; Teresa Rutledge; Elsa Romero; Tudor I Oprea; Larry A Sklar; Edward Bedrick; Charles L Wiggins; Huining Kang; Lesley Lomo; Carolyn Y Muller; Angela Wandinger-Ness; Laurie G Hudson
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

3.  Validated Stability-indicating Reverse-phase Ultra-performance Liquid Chromatography Method for Simultaneous Determination of Sodium Methylparaben, Sodium Propylparaben and Ketorolac Tromethamine in Topical Dosage Forms.

Authors:  C Roy; J Chakrabarty; P B Modi
Journal:  Indian J Pharm Sci       Date:  2013-03       Impact factor: 0.975

4.  New chiral reverse phase HPLC method for enantioselective analysis of ketorolac using chiral AGP column.

Authors:  Sunil K Dubey; Jangala Hemanth; Chiranjeevi Venkatesh K; R N Saha; S Pasha
Journal:  J Pharm Anal       Date:  2012-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.